SubsidieMeestersRevolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
Diamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies.
Projectdetails
Introduction
At Diamante Società Benefit srl, we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP).
Mode of Action
Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotherapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease.
Proof-of-Concept Studies
Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects.
Innovative Approach
Our drug will be the first treatment based on the restoration of self-tolerance while maintaining the immune system’s ability to defend itself, hence reducing potential harmful side effects.
Funding Request
We are now seeking funding to cover the next clinical development steps.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- DIAMANTE SOCIETA BENEFIT S.R.Lpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
NPC Auto-ImmuunDit project ontwikkelt een innovatieve analysetechniek om de effectiviteit van NanoParticle Conjugates voor de behandeling van auto-immuunziekten te onderzoeken via bloedanalyse. | Mkb-innovati... | € 20.000 | 2020 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
Driving tumour antigen presentation by RNA-mediated transdifferentiationDART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution. | ERC Proof of... | € 150.000 | 2024 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargoThe project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods. | ERC Proof of... | € 150.000 | 2022 | Details |
NPC Auto-Immuun
Dit project ontwikkelt een innovatieve analysetechniek om de effectiviteit van NanoParticle Conjugates voor de behandeling van auto-immuunziekten te onderzoeken via bloedanalyse.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Driving tumour antigen presentation by RNA-mediated transdifferentiation
DART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargo
The project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods.